Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2025 16:00 ET | Source: INVENTIVA

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PHLanifibranor was observed to decrease portal pressure by...
February 26, 2025 16:00 ET | Source: INVENTIVA

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor

L'étude a démontré que lanifibranor améliorait l'hypertension portale (HTP) dans des modèles murins d'HTP fibrotique et d'HTP non fibrotique préhépatique Il a été observé que lanifibranor réduit la...
February 24, 2025 08:01 ET | Source: Douglas Dynamics, Inc.

Douglas Dynamics Appoints New President of Work Truck Attachments

MILWAUKEE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Douglas Dynamics, Inc. (NYSE: PLOW), North America’s premier manufacturer and upfitter of work truck attachments and equipment, today announced the...
February 20, 2025 16:00 ET | Source: INVENTIVA

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 studyPositive results could support the initiation of a pivotal Phase 3...
February 12, 2025 17:00 ET | Source: Kinross Gold Corporation

Kinross reports 2024 fourth-quarter and full-year results

Delivered on all key guidance metricsAchieved record free cash flow of more than $1.3 billion and repaid $800 million of debtStrong three-year outlook of 2.0 million Au eq. oz. per year ...
February 10, 2025 16:00 ET | Source: INVENTIVA

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate...
January 29, 2025 16:00 ET | Source: INVENTIVA

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance...
January 28, 2025 11:45 ET | Source: LVMH

LVMH achieves a solid performance despite an unfavorable global economic environment

. Revenue: €84.7 billion. Profit from recurring operations: €19.6 billion. Free cash flow: €10.5 billion. Acceleration in the fourth quarter, driven by Asia, the United States and Europe. Major...
January 24, 2025 16:00 ET | Source: INVENTIVA

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
January 22, 2025 16:00 ET | Source: INVENTIVA

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...